Must RAAS-modifying drugs be withdrawn for the diagnosis of primary aldosteronism?

Clicks: 23
ID: 328465
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #120 of 449 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 449 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Several classes of antihypertensive drugs which act on the renin-angiotensin-aldosterone-system (RAAS) change the measurements in blood of aldosterone or renin, and hence the derived aldosterone-renin-ratio. Since guideline-recommended thresholds of this ratio are used for diagnosing primary aldosteronism, it has been common practice to withdraw potentially interfering drugs several weeks prior to diagnostic tests, in order to reduce the risk of false-positive and false-negative results. This debate highlights two opposing views on the necessity for such withdrawal. The Pro-side of the debate emphasizes the importance of an accurate diagnosis to achieve optimal targeted treatment results. The Con-side accentuates the importance of feasibility, safety and costs of routine adjustment of medication. The data available to evaluate the balance of benefit versus risk of these diagnostic approaches have considerable limitations. Prospective outcome studies of newer tests and treatments present an opportunity to define the optimal strategy for maximizing accurate diagnoses of primary aldosteronism.
Reference Key
openalex_W7212393730 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ada Ee Der Teo, Christina Pamporaki, Jacques W.M. Lenders, Morris J. Brown
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag375
URL
https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgag375/71045121/dgag375.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.